Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2023-11-23 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - ANP 7 pages 35.3KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Antisense Therapeutics Limited regarding a proposed issue of new securities, specifically options with exercise prices and expiry dates. It references shareholder approval obtained at the Annual General Meeting (AGM) held on 15 November 2023. The document details the terms of the securities, conditions, and timetable for the issue. It is a regulatory announcement about a capital raising activity (placement or other type of issue) and does not contain financial statements or detailed financial performance data. The document is about the issuance of new securities and related approvals, fitting the category of Capital/Financing Update rather than a full report or other categories. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-11-23 English
Change of Director's Interest Notice (JG) 2 pages 282.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of shares held before and after the change, the nature of the change (on-market acquisition), and the value per share. This is a clear report of a director's personal share transactions. The document length is 3737 characters, which is consistent with a detailed notice of director dealings rather than a full financial report or announcement. Therefore, the document fits the definition of 'Director's Dealing' (DIRS).
2023-11-20 English
Annual General Meeting Presentation 20 pages 1.7MB
AGM Information Classification · 95% confidence The document is a presentation titled "Positioning Antisense for Success in 2024" delivered at the Annual General Meeting (AGM) of shareholders on 15 November 2023. It contains forward-looking statements, updates on clinical trials, biotech market environment, and company strategy. The content is structured as a presentation with slides, agenda points, and detailed discussion of development programs and market conditions. There is no indication that this is a full annual report or financial statement, nor is it an earnings release or regulatory filing. The presence of the phrase "Presentation to Annual General Meeting of Shareholders" and the format strongly indicate this is material shared during the AGM. Therefore, the document fits the category of AGM Information (AGM-R).
2023-11-14 English
Results of Annual General Meeting 2 pages 257.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of Annual General Meeting' and provides detailed voting results for resolutions passed at the 2023 Annual General Meeting of Antisense Therapeutics Limited. It references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, which pertain to disclosure of AGM voting results. The content includes proxy votes, votes for and against, abstentions, and the outcome of each resolution. There is no indication that this is the full AGM presentation or materials, nor is it a report like an Annual Report or Interim Report. The document is not a notice of a report publication but the actual voting results announcement. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (5215 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2023-11-14 English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 1.5MB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Quarterly Activities Report and Appendix 4C' dated 31 October 2023. It provides a detailed update on the company's quarterly activities, including financial information such as cash balance and payments, progress on clinical trials, equity placement and share purchase plan fundraising, management changes, and other operational updates. The presence of an Appendix 4C (a quarterly cash flow report required by ASX) and substantive financial data and analysis for the quarter ended 30 September 2023 indicates this is a comprehensive interim/quarterly report rather than a brief announcement or a full annual report. The document length (15,000 characters) and detailed content confirm it is not a short announcement or a certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2024
2023-10-30 English
Notice of Annual General Meeting/Proxy Form 29 pages 953.9KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes details about the meeting date, location, and virtual attendance. It contains the agenda for the AGM, including consideration of the Annual Financial Report for the year ended 30 June 2023, resolutions for adoption of the Remuneration Report, re-election of a director, ratification of prior share issues, approval of options issuance, approval of an employee share option plan, and special resolutions such as company name change and placement facility approval. The document also includes explanatory notes, proxy forms, voting prohibition and exclusion statements, and procedural notes for shareholders. The content is consistent with materials typically distributed to shareholders prior to an AGM to inform them of the meeting's business and to solicit their votes. It is not the Annual Report itself, nor a transcript or financial report, but rather the official notice and related explanatory materials for the AGM. Therefore, the correct classification is AGM Information (AGM-R). The document length (15,000 characters) and detailed meeting agenda support this classification with high confidence.
2023-10-16 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.